Unraveling the Internal Drivers of Pharmaceutical Company Performance in Europe: A DEMATEL Analysis

• Autorzy: Arif Ibne Asad , Boris Popesko , Brian Godman
• Języki publikacji: EN

Abstrakty

EN

Research background: Internal business factors are vital to how a company achieves its goals. The present study of internal drivers of pharmaceutical company performance is very insightful, as it has the potential to boost further competitiveness, it may allow health authority personnel to have guidelines to make strategic decisions, as well as inspire investor confidence, ensure regulatory compliance and performance benchmarking, and support talent acquisition and retention. In addition, it can identify the important internal factors that need to receive more priority. Purpose of the article: The European pharmaceutical industry is currently facing multiple challenges. This paper aims to map the relative relationships among the internal factors that influence the business performance of pharmaceutical companies in Europe by using the DEMATEL approach. Method: There are two phases of the present study, an extensive literature review and the use of the decision-making trial and evaluation laboratory (DEMATEL) technique. To identify the key internal drivers and their cause-and-effect relationship with pharmaceutical company performance in Europe, data from experts were obtained using the predesigned DEMATEL questionnaire. Findings & value added: The extensive literature review from the Web of Science and Scopus databases found that seven internal factors are very demanding in the case of European pharmaceutical business performance. The main elements that have the highest impact on pharmaceutical business performance in Europe are human resources competencies, the information system, technological competitiveness, and the patent system. However, financial profitability, research and development competencies, alliances with other companies, and supply chain management are the factors that are affected more by other factors. The study is the first attempt to identify the internal business performance of the pharmaceutical sector in Europe by working with pragmatic and perceptive decisions from pharmaceutical stakeholders in Europe.(original abstract)

Słowa kluczowe

EN

Pharmaceutical company; DEcision MAking Trial and Evaluation Laboratory method

PL

Przedsiębiorstwo farmaceutyczne; Metoda DEMATEL

• Czasopismo: Equilibrium
• Rocznik: 2024
• Tom: 19
• Numer: nr 2
• Strony: 661--702

Twórcy

autor

Arif Ibne Asad

• Tomas Bata University in Zlín, Czech Republic

autor

Boris Popesko

• Tomas Bata University in Zlín, Czech Republic

autor

Brian Godman

• University of Strathclyde, United Kingdom

Bibliografia

• Abbasi, S., Aghakhani, H., Azizi, S., Peikanpour, M., & Mehralian, G. (2023). Corporate social responsibility and customer loyalty during the Covid-19 pandemic: Evidence from pharmacy practise. Social Responsibility Journal, 19(2), 249-263. https://doi.org/10.1108/SRJ-06-2021-0243.
• Alharthi, S. A. K., Cerotti, P., & Far, S. M. (2020). Investigating the impact of block-chain implementation on pharmaceutical supply chain sustainability. In Proceedings paper at 35th International-Business-Information-Management-Association conference (IBIMA) (pp. 9231-9252). IBIMA.
• Araujo, T. R. D., Jugend, D., Pimenta, M. L., Jesus, G. M. K., Barriga, G. D. D. C., Toledo, J. C. D., & Mariano, A. M. (2022). Influence of new product development best practices on performance: An analysis in innovative Brazilian companies. Journal of Business & Industrial Marketing, 37(2), 266-281. https://doi.org/10.1108/JBIM-07-2020-0362
• Asad, A. I., & Popesko, B. (2023). Contemporary challenges in the European phar-maceutical industry: A systematic literature review. Measuring Business Excellence, 27(2), 277-290. https://doi.org/10.1108/MBE-09-2021-0112.
• Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery, 20(3), 200-216. https://doi.org/10.1038/s41573-020-00114-z.
• Bala, H., Massey, A. P., & Montoya, M. M. (2017). The effects of process orientations on collaboration technology use and outcomes in product development. Journal of Management Information Systems, 34(2), 520-559. https://doi.org/10.1080/07421222.2017.1334494
• Ballano, V. (2023). Catholic social teaching, human dignity, and the common good: Exploring the major factors affecting Big Pharma's corporate moral responsibil-ity during COVID-19. Business and Professional Ethics Journal, 42(3), 291-314. https://doi.org/10.5840/bpej20231017145.
• Bereznoy, A. (2022). Transformation of Big Pharma business models. Mirovaia Ekonomika i Mezhdunarodnye Otnosheniia, 66(3), 81-89. https://doi.org/10.20542/0131-2227-2022-66-3-81-89.
• Boddu, R. S. K., Ahamad, S., Kumar, K. P., Ramalingam, M., Pallathadka, L. K., & Tupas, F. P. (2022). Analysis of robotics, artificial intelligence and machine learning in the field of healthcare sector. Materials Today: Proceedings,56, 2323-2327. https://doi.org/10.1016/j.matpr.2021.12.016.
• Boldeanu, D. M., & Gheorghe, M. (2012). Multidimensional analysis of firm's financial performance through the influence factors in pharmaceutical sector. In Proceedings of the international conference accounting and management information sys-tems AMIS 2012 (pp. 1049-1060). Bucharest: Bucharest University of Economic Studies.
• Boldeanu, D. M., & Pugna, I. B. (2014). The analysis of the influence factors affecting the performance of pharmaceutical companies. Theoretical & Applied Economics, 21(7), 23-42.
• Bousalem, R., & Aichouche, K. (2016). Presenting a model of critical success factors for organizational innovation in Algerian Pharmaceutical Company. In 2016 international conference on digital economy (ICDEc) (pp. 45-52). IEEE. doi: 10.1109/ICDEC.2016.7563144.
• Chai, K. C., Tao, R., Chang, K. C., & Yang, Y. (2020). Impact of China's vaccine incidents on the operational efficiency of biopharmaceutical companies. Frontiers in Public Health, 8(93), 1-8. https://doi.org/10.3389/fpubh.2020.00093.
• Ciliberti, S., Carraresi, L., & Bröring, S. (2016). Drivers of innovation in Italy: Food versus pharmaceutical industry. British Food Journal, 118(6), 1292-1316. https://doi.org/10.1108/BFJ-10-2015-0405.
• Dadfar, H., Brege, S., Golizeh, M., & Ghasemi, H. (2010). Corporate governance in pharmaceutical industry: The case of TAPIC pharmaceutical group. In 6th European conference on management, leadership and governance (ECMLG 2010) (pp. 83-93). Academic Conferences Limited.
• de Campos, E. A. R., Tavana, M., Ten Caten, C. S., Bouzon, M., & de Paula, I. C. (2021). A grey-DEMATEL approach for analysing factors critical to the implementation of reverse logistics in the pharmaceutical care process. Environmental Science and Pollution Research, 28(11), 14156-14176. https://doi.org/10.1007/s11356-020-11138-8.
• Doloreux, D., Shearmur, R., & Rodriguez, M. (2016). Determinants of R&D in knowledge-intensive business services firms. Economics of Innovation and New Technology, 25(4), 391-405. https://doi.org/10.1080/10438599.2015.1067001.
• Donkor, F., Papadopoulos, T., & Spiegler, V. (2022). Supply chain integration and supply chain sustainability relationship: A qualitative analysis of the UK and Ghana pharmaceutical industry. Production Planning & Control, 35(6), 535-558. https://doi.org/10.1080/09537287.2022.2105762.
• Downs, J. B., & Velamuri, V. K. (2018). Business model innovation in a knowledge revolution: An evolutionary theory perspective. Managerial and Decision Economics, 39(5), 550-562. https://doi.org/10.1002/mde.2926.
• Du, Y. W., & Zhou, W. (2019). New improved DEMATEL method based on both subjective experience and objective data. Engineering Applications of Artificial Intelligence, 83, 57-71. https://doi.org/10.1016/j.engappai.2019.05.001.
• Enekwe, C. I., Agu, C. I., & Eziedo, K. N. (2014). The effect of financial leverage on financial performance Evidence of quoted pharmaceutical companies in Nigeria. IOSR Journal of Economics and Finance, 5(3), 17-25.
• Estler, M., & Ewen, J. (2011). Overcoming boundaries by "production intelligence". Pharmazeutische Industrie, 73(3), 566-573.
• European Commission (2020). Pharmaceutical strategy for Europe, 2020. Retrieved from https://health.ec.europa.eu/system/files/2021-02/pharma-strategy_report_ en_0.pdf.
• European Parliament (2021). European pharmaceutical research and development: Could public infrastructure overcome market failures? European Parliamentary Research Service, Brussels. Retrieved from https://www.europarl.europa.eu/Reg Data/etudes/STUD/2021/697197/EPRS_STU(2021)697197
• European Parliament (2023). Artificial intelligence: threats and opportunities. Retrieved from https://www.europarl.europa.eu/news/en/headlines/society/202009 18STO87404/artificial-intelligence-threats-and-opportunities.
• Eva, G. (2018). New health technologies as one of the key drivers of healthcare spending growth in the Czech Republic. In Proceedings of the 22nd international conference current trends in public sector research (pp. 244-251). Brno: Masaryk University.
• Ferreira, T. S. (2017). Motivational factors in sales team management and their influence on individual performance. Tourism & Management Studies, 13(1), 60-65. https://doi.org/10.18089/tms.2017.13108.
• Frank, M., Jaeger, L., & Ranft, L. M. (2023). Using contextual factors to predict information security overconfidence: A machine learning approach. Computers & Security, 125, 103046. https://doi.org/10.1016/j.cose.2022.103046.
• Galende, J., & de la Fuente, J. M. (2003). Internal factors determining a firm's innovative behaviour. Research Policy, 32(5), 715-736. https://doi.org/10.1016/S0048-7333(02)00082-3.
• Gaol, F. L., Rahayu, S., & Matsuo, T. (2020). The development of information system with strategic planning for integrated system in the Indonesian pharmaceutical company. Open Engineering, 10(1), 721-732. https://doi.org/10.1515/eng-2020-0081.
• Gascón, F., Lozano, J., Ponte, B., & de la Fuente, D. (2017). Measuring the efficiency of large pharmaceutical companies: An industry analysis. EuropeanJournal of Health Economics, 18(5), 587-608. https://doi.org/10.1007/s10198-016-0812-3.
• Ghauri, E. (2018). Performance evaluation of sales employees: A comparative investigation in the pharmaceutical industry. International Journal of Business Performance Management, 19(3), 253-279. https://doi.org/10.1504/IJBPM.2018.092756.
• Glenn Richey Jr, R., Chen, H., Upreti, R., Fawcett, S. E., & Adams, F. G. (2009). The moderating role of barriers in the relationship between drivers to supply chain integration and firm performance. International Journal of Physical Distribution & Logistics Management, 39(10), 826-840. https://doi.org/10.1108/09600030911011432.
• Hall, L. A., & Bagchi-Sen, S. (2002). A study of R&D, innovation, and business performance in the Canadian biotechnology industry. Technovation, 22(4), 231-244. https://doi.org/10.1016/S0166-4972(01)00016-5.
• Hansen, Z. N. L., Andreu, C. M., Khan, O., Haug, A., Hvam, L., & Hansen, N. E. (2023). Identification of key drivers for improving inventory management in pharmaceutical supply chains. Production Engineering, 17(5), 763-772. https://doi.org/10.1007/s11740-023-01199-2.
• Haque, M., & Islam, R. (2018). Impact of supply chain collaboration and knowledge sharing on organizational outcomes in pharmaceutical industry of Bangladesh. Journal of Global Operations and Strategic Sourcing, 11(3), 301-320. https://doi.org/10.1108/JGOSS-02-2018-0007.
• Hassan, N. A., Mohammad Zailani, S. H., & Hasan, H. A. (2021). A meta-analysis of integrated internal audit management effectiveness towards business sustaina-bility. Pertanika Journal of Social Sciences & Humanities, 29(S2), 233-252. https://doi.org/10.47836/pjssh.29.s2.16.
• Izadpanah, F., Shiehmorteza, M., Rahimpour, A., & Moradi, M. (2020). Prioritizing medication management criteria of national hospital accreditation standards us-ing FDANP model. Journal of Pharmaceutical Research International, 32(3), 69-77. https://doi.org/10.9734/jpri/2020/v32i330415.
• Jaberidoost, M., Nikfar, S., Abdollahiasl, A., & Dinarvand, R. (2013). Pharmaceutical supply chain risks: A systematic review. DARU Journal of Pharmaceutical Sciences, 21(69), 1-7. https://doi.org/10.1186/2008-2231-21-69.
• Jassbi, A., Jafari, M., Mahdavi Mazdeh, M., & Maleki, M. (2021). Structural model of foresightful export-oriented strategies for Iran pharmaceutical industry using the Fuzzy DEMATEL method. Iranian Red Crescent Medical Journal, 23(11), 1-8. https://doi.org/10.32592/ircmj.2021.23.11.1113.
• Jayamohan, P., Moss, T., McKelvie, A., & Hyman, M. (2024). The influence of managerial attributions on corporate entrepreneurship.Journal of Management & Organization, 30(1), 18-39. https://doi.org/10.1017/jmo.2022.7.
• Jiang, H., Wang, Z., Gao, S., Chen, K., & Sheng, F. (2022). Enhancing technology innovation performance through alliance capability: The role of standard alliance network and political skill of TMTs. Frontiers in Psychology, 13, 1008857. https://doi.org/10.3389/fpsyg.2022.1008857.
• Jolly, A., Nicol, L., Waters, J., & Wight, C. (2005). Drivers affecting the pharmaceutical industry: How much is changing?. Journal of Medical Marketing, 5(2), 146-157. https://doi.org/10.1057/palgrave.jmm.5040220.
• Jongh, T., Becker, D., Boulestreau, M., Dave, A., Dijkstal, F., King, R., Petrosova, L., Varnal, P., Vis, C., Spit, W., Moulac, M., & Pelsy, F. (2021). Future-proofing pharmaceutical legislation - Study on medicine shortages - Final report (re-vised), Publications Office of the European Union. Retrieved from https://data.europa.eu/doi/10.2875/211485.
• Kabak, Ö., Ülengin, F., Çekyay, B., Önsel, Ş., & Özaydın, Ö. (2016). Critical success factors for the iron and steel industry in Turkey: A fuzzy DEMATEL approach. International Journal of Fuzzy Systems, 18, 523-536. https://doi.org/10.1007/s40815-015-0067-7.
• Kayani, S. A., Warsi, S. S., & Liaqait, R. A. (2023). A smart decision support frame-work for sustainable and resilient supplier selection and order allocation in the pharmaceutical industry. Sustainability, 15(7), 5962. https://doi.org/10.3390/su15075962.
• Khan, S. A., Gupta, H., Gunasekaran, A., Mubarik, M. S., & Lawal, J. (2023). A hybrid multicriteria decision-making approach to evaluate interrelationships and impacts of supply chain performance factors on pharmaceutical industry. Journal of Multi-Criteria Decision Analysis, 30(1-2), 62-90. https://doi.org/10.1002/mcda.1800.
• Klinge, T. J., Fernandez, R., & Aalbers, M. B. (2020). The financializetion of big pharma. Revista Internacional de Sociologia, 78(4), e174. https://doi.org/10.3989/RIS.2020.78.4.M20.006.
• Kumar, A., Kaviani, M. A., Bottani, E., Dash, M. K., & Zavadskas, E. K. (2018). Investigating the role of social media in polio prevention in India: A Delphi-DEMATEL approach. Kybernetes, 47(5), 1053-1072. https://doi.org/10.1108/K-06-2017-0210.
• Kumar, D., & Chandra, D. (2022). A hybrid framework to model resilience in the generic medicine supply chain of MSMEs. Benchmarking: An International Journal, 30(6), 2189-2224. https://doi.org/10.1108/BIJ-11-2021-0697.
• Lee, H. S., Tzeng, G. H., Yeih, W., Wang, Y. J., & Yang, S. C (2013). Revised DE-MATEL: Resolving the infeasibility of DEMATEL. Applied Mathematical Modelling,37(10-11), 6746-6757. https://doi.org/10.1016/j.apm.2013.01.016.
• Li, X., & Hamblin, D. (2016). Factors impacting on cleaner production: Case studies of Chinese pharmaceutical manufacturers in Tianjin, China. Journal of Cleaner Production, 131, 121-132. https://doi.org/10.1016/j.jclepro.2016.05.066.
• Ling, T. C., Fern, Y. S., Ang, P. T., & Ching, S. L. (2018). Examining the priority variables on the R&D engineer's innovativeness: An importance-performance matrix analysis (IPMA) approach. In ICMLG 2018 6th international conference on management leadership and governance (pp. 69-77). Academic Conferences and Publishing Limited.
• Luu, D. T., Ho, D. P., Hiep, N. T. K., Hoi, P. T., & Hanh, D. T. P. (2019). Job satisfaction, leadership styles, demographic variables, and organisational commitment among pharmacists in Vietnam. South East Asian Journal of Management,13(1), 37-52. https://doi.org/10.21002/seam.v13i1.10693.
• Mahdiraji, H. A., Kamardi, A. A., Beheshti, M., Hajiagha, S. H. R., & Rocha-Lona, L. (2022). Analysing supply chain coordination mechanisms dealing with repur-posing challenges during Covid-19 pandemic in an emerging economy: A multi-layer decision making approach. Operations Management Research, 15(3-4), 1341-1360. https://doi.org/10.1007/s12063-021-00224-w.
• Mahssouni, R., Touijer, M. N., & Makhroute, M. (2022). Employee compensation, training, and financial performance during the COVID-19 pandemic. Journal of Risk and Financial Management, 15(12), 559. https://doi.org/10.3390/jrfm15120559.
• Małys, Ł. (2023). The approach to supply chain cooperation in the implementation of sustainable development initiatives and company's economic performance. Equilibrium. Quarterly Journal of Economics and Economic Policy, 18(1), 255-286. https://doi.org/10.24136/eq.2023.008
• Meidute-Kavaliauskiene, I., Cebeci, H. I., Ghorbani, S., & Činčikaitė, R. (2021). An integrated approach for evaluating lean innovation practices in the pharmaceutical supply chain. Logistics,5(4), 74. https://doi.org/10.3390/logistics5040074.
• Mendigorri, E. M., Valderrama, T. G., & Cornejo, V. R. (2016). Measuring the effectiveness of R & D activities: Empirical validation of a scale in the Spanish pharmaceutical sector. Management Decision, 54(2), 321-362. https://doi.org/10.1108/MD-06-2014-0378.
• Moosivand, A., Ghatari, A. R., & Rasekh, H. R. (2019). Supply chain challenges in pharmaceutical manufacturing companies: Using qualitative system dynamics methodology. Iranian Journal of Pharmaceutical Research: IJPR, 18(2), 1103-1116. https://doi.org/10.22037/ijpr.2019.2389.
• Naeem, R. M., Channa, K. A., Hameed, Z., Ali Arain, G., & Islam, Z. U. (2021). The future of your job represents your future: A moderated mediation model of transformational leadership and job crafting. Personnel Review, 50(1), 207-224. https://doi.org/10.1108/PR-07-2019-0404.
• Nazari, J. A., & Ghasemzadeh, P. (2018). The effects of knowledge creation process on organizational performance using the BSC approach: The mediating role of intellectual capital. Journal of Knowledge Management,22(4), 802-823. https://doi.org/10.1108/JKM-10-2016-0457.
• Nguyen, T. (2021). The effect of internal control on the performance of pharmaceu-tical firms in Vietnam. Accounting, 7(2), 395-400. https://doi.org/10.5267/j.ac.2020.11.012.
• Ohana, P., Tardieu, S., Blin, O., Tassy, S., & Sambuc, R. (2004). Drug patents and other ways to protect pharmaceutical research. Therapie, 59(2), 253-257. https://doi.org/10.2515/therapie:2004049.
• Ombrosi, N., Casprini, E., & Piccaluga, A. (2019). Designing and managing co-innovation: The case of Loccioni and Pfizer. European Journal of Innovation Management, 22(4), 600-616. https://doi.org/0.1108/EJIM-09-2018-0196.
• Ortiz, B., Donate, M. J., & Guadamillas, F. (2021). Intra-organizational social capital and product innovation: The mediating role of realised absorptive capacity. Frontiers in Psychology, 11, 624189. https://doi.org/10.3389/fpsyg.2020.624189.
• Pinto, G., & Rastogi, S. (2022). Corporate governance impact on dividend policy of NIFTY-500 indexed Indian pharmaceutical companies (2014-2019). Corporate Governance, 22(7), 1547-1566. https://doi.org/10.1108/CG-08-2021-0309.
• Pinto, H., Guerreiro, J. A., & Fernández-Esquinas, M. (2023). Sources of knowledge in the firm: A review on influential, internal, and contextual factors in innovation dynamics. SN Business & Economics, 3(57), 1-32. https://doi.org/10.1007/s43546-023-00430-7.
• Raghavendra, M. S., Raj, J. R., & Seetharaman, A. (2012). A study of decrease in R&D spending in the pharmaceutical industry during post-recession. International Journal of Academic Research, 4(5), 29-47. https://doi.org/10.7813.2075-4124.2012/4-5/B.6.
• Riantoputra, D. C. (2010). Know thyself: Examining factors that influence the activation of organizational identity concepts in top managers' minds. Group & Organisation Management, 35(1), 8-38. https://doi.org/10.1177/1059601109354804.
• Rocha, M. D. M., de Andrade, E. P., Alves, E. R., Cândido, J. C., & Borio, M. D. M. (2020). Access to innovative medicines by pharma companies: Sustainable initiatives for global health or useful advertisement?. Global Public Health, 15(6), 777-789. https://doi.org/10.1080/17441692.2020.1729391.
• Rouhani, S., Ashrafi, A., & Afshari, S. (2014). Fuzzy DEMATEL model for evaluation criteria of business intelligence. In International conference on enterprise information systems (pp.456-463). SciTePress.
• Sabary, G. S., & Ključnikov, A. (2023). Barriers to immigrant entrepreneurship: A causal relationship analysis of the Asian immigrant entrepreneurs in Germany employing the DEMATEL approach. Equilibrium.Quarterly Journal of Economics and Economic Policy,18(2), 491-522. https://doi.org/10.24136/eq.2023.015.
• Sabary, G. S., Durda, L., Asad, A. I., & Ključnikov, A. (2023). Key motivational factors behind Asian immigrant entrepreneurship: A causal relationship analysis employing the DEMATEL approach for Germany. Equilibrium. Quarterly Journal of Economics and Economic Policy, 18(1), 275-318. https://doi.org/10.24136/eq.2023.009.
• Schapranow, M. P., Müller, J., Zeier, A., & Plattner, H. (2012). Secure RFID-enablement in modern companies: A case study of the pharmaceutical industry. In Handbook of research on industrial informatics and manufacturing intelligence: Innovations and solutions (pp.507-539).IGI Global.https://doi.org/10.4018/978-1-4666-0294-6.ch022.
• Shafiee, M., Zare-Mehrjerdi, Y., Govindan, K., & Dastgoshade, S. (2022). A causality analysis of risks to perishable product supply chain networks during the COVID-19 outbreak era: An extended DEMATEL method under Pythagorean fuzzy environment. Transportation Research Part E: Logistics and Transportation Review,163, 102759. https://doi.org/10.1016/j.tre.2022.102759.
• Sharma, M., Sehrawat, R., Luthra, S., Daim, T., & Bakry, D. (2022). Moving towards industry 5.0 in the pharmaceutical manufacturing sector: Challenges and solutions for Germany. IEEE Transactions on Engineering Management. 1-18. https://doi.org/10.1109/TEM.2022.3143466.
• Singh, S., Singh, S., & Misra, S. C. (2023). Post-implementation challenges of ERP system in pharmaceutical companies. International Journal of Quality & Reliability Management,40(4), 889-921. https://doi.org/10.1108/IJQRM-10-2020-0333.
• Styhre, A. (2002), The knowledge-intensive company and the economy of sharing: Rethinking utility and knowledge management. Knowledge and Process Management,9, 228-236. https://doi.org/10.1002/kpm.155.
• Subramanian, B., & Bhattacharyya, S. S. (2023). Explicating the factors influencing successful implementation and management of sustainable innovation practices in research-intensive organizations. Journal of Science and Technology Policy Management. https://doi.org/10.1108/JSTPM-05-2023-0067.
• Sun, X., Zuo, L., Zhu, J., & Zhang, K. (2013). The research on business process reen-gineer internal influencing factors. In International academic workshop on social sci-ence (IAW-SC-13) (pp. 218-222). Atlantis Press. https://doi.org/10.2991/iaw-sc.2013.47.
• Tavana, M., Khalili-Damghani, K., & Rahmatian, R. (2015). A hybrid fuzzy MCDM method for measuring the performance of publicly held pharmaceutical compa-nies. Annals of Operations Research, 226, 589-621. https://doi.org/10.1007/s10479-014-1738-8.
• Tetteh, M. G., Jagtap, S., & Salonitis, K. (2022). Pharma 4.0: Revealing drivers of the digital transformation in the pharma sector. In Global conference on sustainable manufacturing (pp. 528-535). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-28839-5_59.
• Timmins, P. (2019). Industry update: The latest developments in the field of therapeutic delivery, 1-31 December 2018. Therapeutic Delivery, 10(4), 215-226. https://doi.org/10.4155/tde-2019-0003.
• Turan, C., & Ozturkoglu, Y. (2022). Investigating the performance of the sustainable cold supply chain in the pharmaceutical industry. International Journal of Pharmaceutical and Healthcare Marketing, 16(3), 448-467. https://doi.org/10.1108/IJPHM-04-2021-0043.
• Um, S. I., Kim, C., Ha, T., Kim, J., & Lee, H. (2022). Morphological change and in-ternal growth factors of firms in the Korean pharmaceutical industry in recent decades. Sustainability, 14(22), 15339. https://doi.org/10.3390/su142215339.
• Van den Bogaert, S., Declercq, J., Christiaens, T., Jacobs, G., & Bracke, P. (2018). In the land of pharma: A qualitative analysis of the reputational discourse of the pharmaceutical industry. Public Relations Inquiry, 7(2), 127-147. https://doi.org/10.1177/2046147X18774588.
• Wisniewski, T., & Tundys, B. (2020). Simulated-based approach to analyse sustainable supply chain in a pharmaceutical company. In Meeting 35th International Business-Information-Management-Association Conference (IBIMA), education excellence and innovation management: A 2025 vision to sustain economic development during global challenges, Spain (pp. 85-96). IBIMA.
• Workman, P., Draetta, G. F., Schellens, J. H., & Bernards, R. (2017). How much longer will we put up with $100,000 cancer drugs?. Cell, 168(4), 579-583. https://doi.org/10.1016/j.cell.2017.01.034.
• Zhang, S., & Zhu, L. (2022). Drugs quality supervision strategy of different distribution channels in pharmaceutical supply chain. Frontiers in Public Health, 10, 1-16, https://doi.org/10.3389/fpubh.2022.954371.

Identyfikatory

DOI

https://doi.org/10.24136/eq.2896